Type I interferon therapies of multiple sclerosis and hepatitis C virus infection

1Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Interferons type I (IFN-I), activated following a bacterial or viral infection, play a major role in the induction and regulation of the immune system. The immune response results in viral RNA and binds to receptors such as RIG-I-like receptors (RLRs) or Toll-like receptors, leading to the IFN-I signaling cascade. Thanks to its cellular function, IFN-I is widely used in therapies for such diseases as multiple sclerosis (MS) and hepatitis C disease (HCD). MS is a neurological, autoimmune, chronic inflammatory disease of the central nervous system (CNS). During MS, nerve cell demyelination is observed due to the myelin heaths and oligodendrocyte damage. As a result, neuronal signal and neuron communication are attenuated. The mechanism of MS is still unknown. MS therapy applies interferon-β (IFN-β). IFN-β therapy has been used since the last century, but the therapeutic mechanism of IFN-β has not been completely understood. MS can lead to four syndromes: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). HCD occurs as a result of infection with the hepatitis C virus (HCV), belonging to the Flaviviridae family. HCV is a bloodborne virus with a positive single-stranded RNA. A vaccine for HCV is not available yet. HCD can lead to liver damage or cancer. In HCD interferon-α therapy (IFN-α) is applied. As with MS, the mechanism of IFN-α therapy is not completely known.

References Powered by Scopus

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

2922Citations
N/AReaders
Get full text

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis

2422Citations
N/AReaders
Get full text

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

2322Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Specimen type validation and establishment of normal cytokine reference intervals in cerebrospinal fluid

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jasyk, I., & Siednienko, J. (2021). Type I interferon therapies of multiple sclerosis and hepatitis C virus infection. Postepy Higieny i Medycyny Doswiadczalnej, 75(1), 537–547. https://doi.org/10.2478/AHEM-2021-0001

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

100%

Readers' Discipline

Tooltip

Neuroscience 4

57%

Medicine and Dentistry 2

29%

Biochemistry, Genetics and Molecular Bi... 1

14%

Save time finding and organizing research with Mendeley

Sign up for free